Literature DB >> 10844589

Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.

C F Franssen1, C A Stegeman, C G Kallenberg, R O Gans, P E De Jong, S J Hoorntje, J W Tervaert.   

Abstract

Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Wegener's granulomatosis, microscopic polyangiitis, and idiopathic pauci-immune necrotizing crescentic glomerulonephritis (NCGN) are strongly associated with antineutrophil cytoplasmic autoantibodies (ANCAs) directed against either proteinase 3 (anti-PR3) or myeloperoxidase (anti-MPO). This has led some investigators to prefer combining these diseases under the common heading of ANCA-associated vasculitides. However, it is increasingly recognized that there are characteristic differences between patients with anti-PR3 and those with anti-MPO-associated vasculitis. This review focuses on the clinical, histopathologic, and possibly pathophysiologic differences between anti-PR3- and anti-MPO-associated vasculitis. Although there is considerable overlap, the anti-PR3- and anti-MPO-associated vasculitides are each characterized by particular clinical and histopathological findings. Extrarenal organ manifestations and respiratory tract granulomas occur more frequently in patients with anti-PR3 than in those with anti-MPO. Anti-PR3-positive patients with NCGN generally have a more dramatic deterioration of their renal function compared with anti-MPO-positive patients. The term "ANCA-associated vasculitis" is considered as a useful concept in the presence of systemic vasculitis. Likewise, in the presence of vasculitis, the terms "anti-PR3-associated vasculitis" and "anti-MPO-associated vasculitis" are useful concepts.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10844589     DOI: 10.1046/j.1523-1755.2000.00080.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  59 in total

Review 1.  Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up?

Authors:  Jan Willem Cohen Tervaert; Jan Damoiseaux
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

2.  Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: a metaanalysis and metaregression.

Authors:  Panupong Hansrivijit; Angkawipa Trongtorsak; Kinjal P Gadhiya; Kriti Lnu; Christina T Dimech; Charat Thongprayoon; Wisit Cheungpasitporn; Stewart H Lecker
Journal:  Clin Rheumatol       Date:  2021-01-15       Impact factor: 2.980

3.  Extra corporeal membrane oxygenation and plasmapheresis for pulmonary hemorrhage in microscopic polyangiitis.

Authors:  Hemant Shyam Agarwal; Mary Barraza Taylor; Marek Janusz Grzeszczak; Harold Newt Lovvorn; Tracy Earl Hunley; Kathy Jabs; Venkatramanan Shankar
Journal:  Pediatr Nephrol       Date:  2005-02-16       Impact factor: 3.714

4.  Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology.

Authors:  Sevil Kamali; Bahar Artim-Esen; Burak Erer; Lutfiye Ozdener; Ahmet Gul; Lale Ocal; Orhan Aral; Murat Inanc
Journal:  Clin Rheumatol       Date:  2011-08-04       Impact factor: 2.980

Review 5.  Key advances in the clinical approach to ANCA-associated vasculitis.

Authors:  Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2014-07-01       Impact factor: 20.543

6.  Audit of the clinical usefulness of a rapid qualitative ELISA screen for antimyeloperoxidase and antiproteinase 3 antibodies in the assessment of patients with suspected vasculitis.

Authors:  A Aslam; T L Newman; S A Misbah
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

7.  C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis.

Authors:  Adrian Schreiber; Hong Xiao; J Charles Jennette; Wolfgang Schneider; Friedrich C Luft; Ralph Kettritz
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

8.  Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis.

Authors:  V C Primo; S Marusic; C C Franklin; W H Goldmann; C G Achaval; R N Smith; M A Arnaout; B Nikolic
Journal:  Clin Exp Immunol       Date:  2009-12-14       Impact factor: 4.330

Review 9.  Immunotherapy for myeloid leukemias: current status and future directions.

Authors:  K el-Shami; B D Smith
Journal:  Leukemia       Date:  2008-06-19       Impact factor: 11.528

10.  ANCA-Positive Patients: The Influence of PR3 and MPO Antibodies on Survival Rate and The Association with Clinical and Laboratory Characteristics.

Authors:  J C Drooger; A Dees; A J G Swaak
Journal:  Open Rheumatol J       Date:  2009-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.